Politics By Rachel Cohrs Pelosi working to gather support for last-minute, last-ditch drug pricing policy
Politics By Nicholas Florko Underpinning Sinema’s outspoken opposition to major drug pricing reforms: her close ties to Arizona biotechs
Exclusive By Rachel Cohrs and Nicholas Florko Key Senate committee considers a carveout for small biotech companies in drug pricing reforms
Politics By Rachel Cohrs Insulin giants Eli Lilly and Novo Nordisk boosted their lobbying spending as Democrats eyed pricing reform
D.C. Diagnosis By Nicholas Florko What does the Build Back Better Act actually mean for the health care industry?
Politics By Rachel Cohrs and Nicholas Florko In May, 10 moderate Democrats opposed major drug pricing reform. Ahead of a key vote, that list is shrinking
Politics By Rachel Cohrs Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?